These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9750511)

  • 21. Bone-turnover metabolites as clinical markers of bone metastasis in patients with prostatic carcinoma.
    Takeuchi S; Saitoh H
    Int J Urol; 1997 Jul; 4(4):368-73. PubMed ID: 9256326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
    Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
    Ikeda I; Miura T; Kondo I
    Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease.
    Topkan E; Karaoglu A
    J Exp Clin Cancer Res; 2007 Dec; 26(4):553-9. PubMed ID: 18365552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
    Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
    Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary tissue factor levels in patients with bladder and prostate cancer.
    Lwaleed BA; Francis JL; Chisholm M
    Eur J Surg Oncol; 2000 Feb; 26(1):44-9. PubMed ID: 10718179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of biochemical indices as metastatic markers in patients with prostatic cancer invading skeleton].
    Liubimova NV; Trapeznikova MF; Robins SP; Ognerubov SA; Kushlinskiĭ NE
    Urologiia; 2000; (4):15-9. PubMed ID: 11186686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y; Tokue A
    Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M; Yonese J; Fukui I; Ogata E
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
    Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
    Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
    Igawa T; Sakai H; Kanetake H; Saito Y
    Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
    Takahashi S
    Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases.
    Zafeirakis AG; Papatheodorou GA; Limouris GS
    Nucl Med Commun; 2010 Mar; 31(3):249-53. PubMed ID: 20038858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical evaluation on serum osteocalcin in advanced prostate cancer patients].
    Abe H; Nakagami YJ; Ito H; Ikeda K; Oka F; Niwa N
    Hinyokika Kiyo; 1991 Aug; 37(8):877-80. PubMed ID: 1720275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
    Hegele A; Wahl HG; Varga Z; Sevinc S; Koliva L; Schrader AJ; Hofmann R; Olbert P
    BJU Int; 2007 Feb; 99(2):330-4. PubMed ID: 17092281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis.
    Sano M; Kushida K; Takahashi M; Ohishi T; Kawana K; Okada M; Inoue T
    Br J Cancer; 1994 Oct; 70(4):701-3. PubMed ID: 7917922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis.
    Nur E; Mairuhu W; Biemond BJ; van Zanten AP; Schnog JJ; Brandjes DP; Otten HM;
    Am J Hematol; 2010 Nov; 85(11):902-4. PubMed ID: 20882525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.